Company
Headquarters: Lund, Sweden
Employees: 26
CEO: Ms. Therese Filmersson
kr648.0 Million
SEK as of Jan. 1, 2024
US$64.4 Million
Company | Market Cap (USD) |
---|---|
Zoetis Inc. | $89.09 B |
MERCK Kommanditgesellschaft auf Aktien | $67.64 B |
Takeda Pharmaceutical Company Limited | $47.71 B |
Haleon plc | $38.90 B |
PPD, Inc. | $16.58 B |
Company | Market Cap (USD) |
---|---|
Lilly | $586.39 B |
UnitedHealth Group | $504.47 B |
Novo Nordisk | $461.52 B |
Johnson & Johnson | $387.50 B |
Merck | $296.51 B |
Enzymatica AB, a life science company, develops and sells medical devices for infection-related diseases in Sweden and internationally. Its product includes ColdZyme mouth spray, which prevents cold and reduces the duration of illness. The company also provides ColdZyme mouth spray under the PreCold name in Iceland; ViruProtect name in Austria and Belgium; ColdGuard name in South Africa; Zerinol Virus Defense in Italy; and Psysiomer Stop Virus in France. It also offers STADAProtect, a mouth spray to protect and care oral cavity, as well as enzyme formulations. Enzymatica AB was incorporated in 2007 and is headquartered in Lund, Sweden.
Top 1-year algo backtest: +269.94%
$10,000 in May 2023 would now be $36,994 by following this algorithm daily at market close.
Boost your stocks returns with Disfold AI... Now!
Try Disfold AI for FREE
Enzymatica AB has the following listings and related stock indices.
Stock: OMX: ENZY wb_incandescent
Stock: FSX: EN9 wb_incandescent